Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Abiraterone
Related studies linked through entity extraction aliases.
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Status
- RECRUITING
- Phase
- PHASE3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
- Status
- RECRUITING
- Phase
- PHASE3
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
- Status
- RECRUITING
- Phase
- PHASE2
SNV1521 in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2